News

Humana Inc. (NYSE: HUM), a leading health and well-being company, today announced a new multi-year agreement with Google Cloud to further modernize Humana’s cloud infrastructure and leverage

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms

Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2024.

CEO, Dr

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2024.

Highlights and Outlook

• 
  Q2 sales grew 7%; constant currency¹ sales grew 8%
  


• 
  Q2 TAVR

CenterWell, the health care services business of Humana Inc. (NYSE: HUM), today announced plans to lease clinical space and open senior-focused primary care centers at 23 Walmart Supercenter retail

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported on Pfizer Inc.’s announcement of positive topline results from the Phase 3 AFFINE trial (NCT04370054)

Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2024 fourth quarter and full year on Tuesday, August 20, 2024, at approximately 6:30 a.m. ET. The

Regulatory News:

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second

Leading health and well-being company Humana Inc. (NYSE: HUM), through its payor-agnostic insurance brokerage business, today announced a minority investment in Healthpilot, a company pioneering

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at

Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2024 after the stock market closes on Aug. 21. In addition, the company will host a

Humana Inc. (NYSE: HUM) scored 100 on the Disability Equality Index® for the fifth consecutive year, demonstrating the company’s continued commitment to building and maintaining a culture of

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2024 financial